Samsung BioLogics Details End-To-End Services

Samsung BioLogics Details End-To-End Services

CDO Team Lead at Samsung BioLogics, Eun Young Yang, shares insight on the company’s one-stop CDMO offerings

At BIO 2018, Eun Young Yang, CDO team lead at Samsung BioLogics, spoke with Contract Pharma about the company's one-stop CDMO services.

Established in 2011, Samsung BioLogics is a joint venture between Samsung affiliate companies and Quintiles Transnational Corp. serving the biopharmaceutical manufacturing industry. The full service provider offers quality driven cGMP contract manufacturing for the global biopharmaceutical industry. Facilities are flexibly designed for cost effective production of monoclonal and recombinant drug substance and drug product.

Ms. Yang detailed Samsung BioLogics' fully integrated end-to-end development and manufacturing services, including cell line generation, process development, analytical services, clinical and commercial bulk cGMP manufacturing, fill/finish, quality control, and project management.

For more information, please visit
Related Searches:
Suggested For You

Related Videos